Ainos, Inc. (AIMD) is a Technology stock trading at $1.41 (as of 2026-08-20), with a market capitalization of $12.02M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Ainos, Inc. develops medical technologies for point-of-care testing and treatment approaches. Its offerings include COVID-19 antigen rapid test kits and a cloud-based test management application, COVID-19 nucleic acid testing, volatile organic compound point-of-care testing, and oral interferon alpha formulations, with additional synthetic RNA technology activities in Taiwan.
Ainos, Inc. develops medical technologies for point-of-care testing and treatment for disease indications, including COVID-19 antigen and nucleic acid tests, volatile organic compounds point-of-care testing, a cloud-based test management app, and Very Low-Dose Oral Interferon Alpha.
Its offerings combine point-of-care diagnostic tests and a cloud-based test management application, so profitability is driven by whether those products and the app generate enough revenue to cover operating costs.
Business quality (Weak): Product scope is clear from the provided description, but no reportable segments, operating KPIs, or peer comparables are provided, limiting the ability to benchmark performance drivers.
| Price | $1.41 |
| Market Cap | $12.02M |
| Price / Book | 3.66 |
| Price / Sales | 883.79 |
| FCF Yield | -37.4% |
| Revenue (TTM) | $124157.00 |
| Net Margin | -11897.0% |
| Revenue Growth (YoY) | -96.7% |
| EPS Growth (YoY) | -37.4% |
| FCF Growth (YoY) | 8.3% |
| Altman Z-Score | -6.27 (distress) |
| Sector P/E (Technology) | 33.9 |
| Industry P/E (Computers) | 32.1 |
| Top Institutional Holder | RENAISSANCE TECHNOLOGIES LLC ($108732.00) |
| Institutional Holders Tracked | 10 |
| Sector | Technology |
| Industry | Computers |
| CEO | Chun-Hsien Tsai |
| Employees | 44 |
| Country | US |
| IPO Date | 2021-01-08 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.